CA3088926A1 - Pyridone derivative, composition and use as antiviral drug thereof - Google Patents
Pyridone derivative, composition and use as antiviral drug thereof Download PDFInfo
- Publication number
- CA3088926A1 CA3088926A1 CA3088926A CA3088926A CA3088926A1 CA 3088926 A1 CA3088926 A1 CA 3088926A1 CA 3088926 A CA3088926 A CA 3088926A CA 3088926 A CA3088926 A CA 3088926A CA 3088926 A1 CA3088926 A1 CA 3088926A1
- Authority
- CA
- Canada
- Prior art keywords
- ring
- carbonyl
- hydrocarbyl
- page
- stereoisomer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/22—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed systems contains four or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/22—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/20—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
- C07F9/65616—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings containing the ring system having three or more than three double bonds between ring members or between ring members and non-ring members, e.g. purine or analogs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Virology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Communicable Diseases (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Pulmonology (AREA)
- Biochemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pyridine Compounds (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810044308.4A CN110041327B (zh) | 2018-01-17 | 2018-01-17 | 吡啶酮衍生物、其组合物及作为抗流感病毒药物的应用 |
| CN201810044308.4 | 2018-01-17 | ||
| CN201811517425.4 | 2018-12-12 | ||
| CN201811517425.4A CN111303147B (zh) | 2018-12-12 | 2018-12-12 | 吡啶酮衍生物、其组合物及作为抗流感病毒药物的应用 |
| PCT/CN2019/071902 WO2019141179A1 (zh) | 2018-01-17 | 2019-01-16 | 吡啶酮衍生物、其组合物及作为抗流感病毒药物的应用 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3088926A1 true CA3088926A1 (en) | 2019-07-25 |
Family
ID=67301986
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3088926A Pending CA3088926A1 (en) | 2018-01-17 | 2019-01-16 | Pyridone derivative, composition and use as antiviral drug thereof |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US11247993B2 (https=) |
| EP (1) | EP3753936B1 (https=) |
| JP (1) | JP7352297B2 (https=) |
| KR (1) | KR102477187B1 (https=) |
| CN (4) | CN111848615B (https=) |
| AU (1) | AU2019210414B2 (https=) |
| CA (1) | CA3088926A1 (https=) |
| PH (1) | PH12020551264A1 (https=) |
| SG (1) | SG11202011447UA (https=) |
| WO (1) | WO2019141179A1 (https=) |
| ZA (1) | ZA202007143B (https=) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2881776T3 (es) | 2016-03-08 | 2021-11-30 | Novartis Ag | Compuestos tricíclicos útiles para tratar las infecciones por ortomixovirus |
| JOP20170169A1 (ar) | 2016-08-29 | 2019-01-30 | Novartis Ag | مركبات بيريدازين ثلاثية الحلقة مندمجة تفيد في علاج العدوى بفيروس أورثوميكسو |
| JP6924839B2 (ja) | 2017-10-06 | 2021-08-25 | 塩野義製薬株式会社 | 置換された多環性ピリドン誘導体の立体選択的な製造方法 |
| KR20230031990A (ko) | 2018-02-28 | 2023-03-07 | 노파르티스 아게 | 인플루엔자의 치료를 위한 오르토믹소바이러스 복제의 억제제로서의 10-(디(페닐)메틸)-4-히드록시-8,9,9a,10-테트라히드로-7h-피롤로[1',2':4,5]피라지노[1,2-b]피리다진-3,5-디온 유도체 및 관련 화합물 |
| WO2020205835A1 (en) * | 2019-04-01 | 2020-10-08 | Nikang Therapeutics, Inc. | Fused polycyclic pyridone compounds as influenza virus replication inhibitors |
| CN111909174B (zh) | 2019-05-08 | 2022-01-21 | 江西彩石医药科技有限公司 | 吡啶酮衍生物的晶型及制备方法和应用 |
| CN112574170A (zh) * | 2019-09-29 | 2021-03-30 | 江西东邦药业有限公司 | 一种二苯并七元环衍生物及其制备方法和应用 |
| CN118480041A (zh) * | 2019-12-23 | 2024-08-13 | 石家庄迪斯凯威医药科技有限公司 | 取代的多环化合物及其药物组合物和用途 |
| CN113045589B (zh) * | 2019-12-27 | 2024-08-23 | 广东东阳光药业股份有限公司 | 流感病毒复制抑制剂及其用途 |
| CN112898346B (zh) * | 2020-01-23 | 2023-11-10 | 南京知和医药科技有限公司 | 水溶性多环化合物及其药物组合物和用途 |
| CN113116899B (zh) * | 2020-03-06 | 2022-12-20 | 广东众生睿创生物科技有限公司 | 一种用于治疗流感的药物组合物及含有该药物组合物的制剂 |
| CN111943879A (zh) * | 2020-08-03 | 2020-11-17 | 南通大学 | 一种（3s，4r）3-氨基-4（甲氧基甲基）吡咯烷-1-甲酸叔丁酯及其合成方法 |
| CN120289488A (zh) * | 2020-08-11 | 2025-07-11 | 石家庄迪斯凯威医药科技有限公司 | 多环化合物及其药物组合物和用途 |
| WO2022247759A1 (zh) * | 2021-05-22 | 2022-12-01 | 江西彩石医药科技有限公司 | 吡啶酮衍生物的中间体及其制备方法 |
| WO2024074080A1 (zh) * | 2022-10-08 | 2024-04-11 | 石家庄迪斯凯威医药科技有限公司 | 一种抗流感病毒衍生物及其用途 |
| CN117924325A (zh) * | 2022-11-09 | 2024-04-26 | 石家庄迪斯凯威医药科技有限公司 | 一种抗流感病毒衍生物及其用途 |
| CN116789556A (zh) * | 2023-05-26 | 2023-09-22 | 康化（上海）新药研发有限公司 | 一种含环丙氧基乙胺的制备方法 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| LT2444400T (lt) | 2009-06-15 | 2018-06-11 | Shionogi & Co., Ltd. | Pakeistasis policiklinis karbamoilpiridono darinys |
| MX2013003139A (es) | 2010-09-24 | 2013-06-18 | Shionogi & Co | Profarmaco de derivado de carbamoilpiridona policiclica substituida. |
| WO2015038655A1 (en) * | 2013-09-12 | 2015-03-19 | Alios Biopharma, Inc. | Aza-pyridone compounds and uses thereof |
| MX394421B (es) * | 2015-04-28 | 2025-03-24 | Shionogi & Co | Derivados de piridona policiclica sustituida y profarmaco de los mismos |
| BR112017022550B1 (pt) * | 2015-04-28 | 2021-02-23 | Shionogi & Co., Ltd | derivados policíclicos de piridona substituída |
| AU2016374416A1 (en) | 2015-12-15 | 2018-06-14 | Shionogi & Co., Ltd. | Medicine for treating influenza characterized by comprising combination of cap-dependent endonuclease inhibitor with anti-influenza drug |
| JP6806413B2 (ja) * | 2016-02-03 | 2021-01-06 | 塩野義製薬株式会社 | 多環性ピリドン誘導体およびそのプロドラッグ |
| RU2727962C1 (ru) | 2016-08-10 | 2020-07-28 | Сионоги Энд Ко., Лтд. | Фармацевтические композиции, содержащие замещенные полициклические пиридоновые производные и их пролекарство |
| JOP20170169A1 (ar) | 2016-08-29 | 2019-01-30 | Novartis Ag | مركبات بيريدازين ثلاثية الحلقة مندمجة تفيد في علاج العدوى بفيروس أورثوميكسو |
-
2019
- 2019-01-16 CN CN202010817434.6A patent/CN111848615B/zh active Active
- 2019-01-16 CN CN202010817435.0A patent/CN111848616B/zh active Active
- 2019-01-16 EP EP19741336.2A patent/EP3753936B1/en active Active
- 2019-01-16 SG SG11202011447UA patent/SG11202011447UA/en unknown
- 2019-01-16 US US16/487,088 patent/US11247993B2/en active Active
- 2019-01-16 KR KR1020207023803A patent/KR102477187B1/ko active Active
- 2019-01-16 JP JP2020560532A patent/JP7352297B2/ja active Active
- 2019-01-16 CN CN202010817035.XA patent/CN111848614B/zh active Active
- 2019-01-16 CN CN201980000078.4A patent/CN110637016B/zh active Active
- 2019-01-16 CA CA3088926A patent/CA3088926A1/en active Pending
- 2019-01-16 WO PCT/CN2019/071902 patent/WO2019141179A1/zh not_active Ceased
- 2019-01-16 AU AU2019210414A patent/AU2019210414B2/en active Active
-
2020
- 2020-08-17 PH PH12020551264A patent/PH12020551264A1/en unknown
- 2020-11-16 ZA ZA2020/07143A patent/ZA202007143B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2019210414B2 (en) | 2021-04-01 |
| EP3753936A4 (en) | 2022-03-23 |
| EP3753936A1 (en) | 2020-12-23 |
| PH12020551264A1 (en) | 2021-05-31 |
| CN111848615B (zh) | 2022-05-17 |
| AU2019210414A1 (en) | 2020-09-03 |
| US11247993B2 (en) | 2022-02-15 |
| SG11202011447UA (en) | 2020-12-30 |
| CN110637016A (zh) | 2019-12-31 |
| ZA202007143B (en) | 2022-04-28 |
| KR20200118062A (ko) | 2020-10-14 |
| US20190367517A1 (en) | 2019-12-05 |
| CN111848615A (zh) | 2020-10-30 |
| WO2019141179A1 (zh) | 2019-07-25 |
| JP2021511374A (ja) | 2021-05-06 |
| JP7352297B2 (ja) | 2023-09-28 |
| CN111848616B (zh) | 2021-11-23 |
| EP3753936B1 (en) | 2026-04-08 |
| CN111848616A (zh) | 2020-10-30 |
| CN111848614A (zh) | 2020-10-30 |
| CN111848614B (zh) | 2021-11-23 |
| CN110637016B (zh) | 2020-08-18 |
| KR102477187B1 (ko) | 2022-12-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA3088926A1 (en) | Pyridone derivative, composition and use as antiviral drug thereof | |
| US5395839A (en) | Imidazopyridine derivatives and their use | |
| CN110041327B (zh) | 吡啶酮衍生物、其组合物及作为抗流感病毒药物的应用 | |
| CA3008607A1 (en) | A medicament for treating influenza characterized by combining a cap-dependent endonuclease inhibitor and an anti-influenza drug | |
| WO2012119941A1 (en) | Peptidyl nitrilcompounds as peptidase inhibitors | |
| RU2637945C2 (ru) | Производные 1-фенил-2-пиридинил-алкиловых спиртов в качестве ингибиторов фосфодиэстеразы | |
| SG177176A1 (en) | 6,7,8, 9 -tetrahydro- 5h- pyrimido[4, 5-d] azepin-4-yl] –amine derivatives as modulators of trpvl for the treatment of pain | |
| KR101419320B1 (ko) | 2-(치환된-아미노)-벤조티아졸 설폰아미드 ｈｉｖ 프로테아제 저해제 | |
| TWI393708B (zh) | 異羥肟酸脂化合物，其用途及其之合成方法 | |
| CA3116830A1 (en) | Heteroaromatic compounds as vanin inhibitors | |
| EA029030B1 (ru) | Пептидилнитрильные соединения в качестве ингибиторов дипептидилпептидазы i | |
| AU2016227618A1 (en) | Peptidyl nitril compounds as dipeptidyl peptidase I inhibitors | |
| CN111303147B (zh) | 吡啶酮衍生物、其组合物及作为抗流感病毒药物的应用 | |
| AU715493B2 (en) | Selective beta 3 adrenergic agonists | |
| KR20240154590A (ko) | Lpa 수용체 활성과 연관된 상태를 치료하기 위한 화합물 및 조성물 | |
| CA3131388A1 (en) | Pyrazolopyridine compounds for ire1 inhibition | |
| CA3188602A1 (en) | Pyrazolopyridine compounds and methods of inhibiting ire1 using same | |
| HK40032909A (en) | Pyridone derivative, composition thereof and application thereof as anti-influenza drug | |
| CA2884767A1 (en) | Imidazopyridine derivatives | |
| EA045400B1 (ru) | Пиридоновое производное, его композиция и применение в качестве противовирусного лекарственного средства | |
| MXPA02002623A (es) | Derivados de bencimidazol sustituidos, procedimiento para su preparacion y su empleo como medicamentos. | |
| KR20240089560A (ko) | 기질 금속단백질분해효소 저해제로서 유용한 다이아자바이사이클로옥탄 유도체 | |
| NZ530154A (en) | Naphthothiazine positive allosteric AMPA receptor modulators ( PAARM ) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20200716 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 6TH ANNIV.) - STANDARD Year of fee payment: 6 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20241001 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20241001 Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20241001 |
|
| D00 | Search and/or examination requested or commenced |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D00-D149 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S INTERVIEW Effective date: 20241106 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - VOLUNTARY AMENDMENT Effective date: 20241125 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20250131 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT Effective date: 20250311 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED Effective date: 20250311 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 7TH ANNIV.) - STANDARD Year of fee payment: 7 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20251210 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20251210 |